RA的名称

HIV感染的治疗

RA ID

88

RA的关键词

immunodeficiency virus type; human immunodeficiency virus; human immunodeficiency virus type; immunodeficiency virus; virus type; antiretroviral therapy; human immunodeficiency; anti-human immunodeficiency virus type; antiretroviral therapy in; highly active antiretroviral therapy

包含RF数(Hot RF数)

核心论文数

去重被引次数

总被引次数

平均出版年

9(2)

95

3970

7471

2004.5

该RA中包含RF的图谱

RF ID

核心论文数

去重被引次数

总被引次数

平均出版年

是否为热点

7281

31

1188

3146

2004.7

No

RF的关键词

broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2g12; human immunodeficiency virus type 1 glycoprotein gp120; acute human immunodeficiency virus type 1 subtype c infection

论文题目

被引

年份

刊名

卷

期

第一作者

antibody neutralization and escape by hiv-1

449

2003

NATURE

422

6929

WEI XP

rapid evolution of the neutralizing antibody response to hiv type 1 infection

249

2003

PROC NAT ACAD SCI USA

100

7

RICHMAN DD

the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2g12 recognizes a cluster of alpha 1 -> 2 mannose residues on the outer face of gp120

199

2002

J VIROL

76

14

SCANLAN CN

carbohydrate arrays for the evaluation of protein binding and enzymatic modification

192

2002

CHEM BIOL

9

4

HOUSEMAN BT

antibody domain exchange is an immunological solution to carbohydrate cluster recognition

166

2003

SCIENCE

300

5628

CALARESE DA

the mannose-dependent epitope for neutralizing antibody 2g12 on human immunodeficiency virus type 1 glycoprotein gp120

165

2002

J VIROL

76

14

SANDERS RW

oligosaccharide microarrays for high-throughput detection and specificity assignments of carbohydrate-protein interactions

144

2002

NAT BIOTECHNOL

20

10

FUKUI S

comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

141

2004

J VIROL

78

23

BINLEY JA

printed covalent glycan array for ligand profiling of diverse glycan binding proteins

136

2004

PROC NAT ACAD SCI USA

101

49

BLIXT O

structure of an unliganded simian immunodeficiency virus gp120 core

128

2005

NATURE

433

7028

CHEN B

envelope-constrained neutralization-sensitive hiv-1 after heterosexual transmission

107

2004

SCIENCE

303

5666

DERDEYN CA

maleimide-functionalized self-assembled monolayers for the preparation of peptide and carbohydrate biochips

96

2003

LANGMUIR

19

5

HOUSEMAN BT

human immunodeficiency virus type 1 env clones from acute and early subtype b infections for standardized assessments of vaccine-elicited neutralizing antibodies

94

2005

J VIROL

79

16

LI M

delay of hiv-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies

90

2005

NATURE MED

11

6

TRKOLA A

structure of a v3-containing hiv-1 gp120 core

87

2005

SCIENCE

310

5750

HUANG CC

cardiolipin polyspecific autoreactivity in two broadly neutralizing hiv-1 antibodies

86

2005

SCIENCE

308

5730

HAYNES BF

structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2f5 in complex with its gp41 epitope

81

2004

J VIROL

78

19

OFEK G

distribution and three-dimensional structure of aids virus envelope spikes

68

2006

NATURE

441

7095

ZHU P

carbohydrate chips for studying high-throughput carbohydrate-protein interactions

64

2004

J AM CHEM SOC

126

15

PARK S

the use of carbohydrate microarrays to study carbohydrate-cell interactions and to detect pathogens

63

2004

CHEM BIOL

11

12

DISNEY MD

gp120: target for neutralizing hiv-1 antibodies

57

2006

ANNU REV IMMUNOL

24

PANTOPHLET R

structural definition of a conserved neutralization epitope on hiv-1 gp120

47

2007

NATURE

445

7129

ZHOU TQ

dissection of the carbohydrate specificity of the broadly neutralizing-anti-hiv-1 antibody 2g12

46

2005

PROC NAT ACAD SCI USA

102

38

CALARESE DA

carbohydrate microarrays: an advanced technology for functional studies of glycans

46

2005

CHEM-EUR J

11

10

SHIN I

neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent hiv infection

44

2005

PROC NAT ACAD SCI USA

102

51

FROST SDW

microarrays of synthetic heparin oligosaccharides

31

2006

J AM CHEM SOC

128

9

DE PAZ JL

carbohydrate microarray for profiling the antibodies interacting with globo h tumor antigen

27

2006

PROC NAT ACAD SCI USA

103

1

HUANG CY

neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype c infection

12

2007

J VIROL

81

12

GRAY ES

antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a dna prime-protein boost immunization strategy

11

2007

J VIROL

81

8

LAW M

cross-reactive hiv-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (r2) with broadly hiv-1 neutralizing antibodies

11

2007

VIROLOGY

363

1

CHOUDHRY V

rational modifications of hiv-1 envelope glycoproteins for immunogen design

9

2007

CURR PHARM DESIGN

13

2

PHOGAT S

RF ID

核心论文数

去重被引次数

总被引次数

平均出版年

是否为热点

6534

22

382

1142

2005.6

No

RF的关键词

human immunodeficiency virus type 1 coreceptor tropism; human immunodeficiency virus type 1 coreceptor switching; cxcr4-using human immunodeficiency virus type 1 (hiv-1) variants; novel hiv-1 integrase inhibitors

论文题目

被引

年份

刊名

卷

期

第一作者

integrase inhibitors to treat hiv/aids

122

2005

NAT REV DRUG DISCOV

4

3

POMMIER Y

diketo acid inhibitor mechanism and hiv-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes

110

2002

PROC NAT ACAD SCI USA

99

10

GROBLER JA

integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques

92

2004

SCIENCE

305

5683

HAZUDA DJ

efficacy of short-term monotherapy with maraviroc, a new ccr5 antagonist, in patients infected with hiv-1

87

2005

NATURE MED

11

11

FATKENHEUER G

design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of hiv-1 integrase in vitro and in infected cells

86

2003

J MED CHEM

46

4

ZHUANG LC

maraviroc (uk-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor ccr5 with broad-spectrum anti-human immunodeficiency virus type 1 activity

74

2005

ANTIMICROB AGENTS CHEMOTHER

49

11

DORR P

a naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of hiv-1 integrase

72

2004

PROC NAT ACAD SCI USA

101

31

HAZUDA DJ

ccr5 deficiency increases risk of symptomatic west nile virus infection

63

2006

J EXP MED

203

1

GLASS WG

durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced hiv-1-infected patients at 48 weeks in the randomized evaluation of strategic intervention in multi-drug...

58

2006

LANCET

368

9534

HICKS CB

the ccr5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive hiv entry inhibitor

55

2005

MOL PHARMACOL

67

4

WATSON C

antiretroviral activity, pharmacokinetics, and tolerability of mk-0518, a novel inhibitor of hiv-1 integrase, dosed as monotherapy for 10 days in treatment-naive hiv-1-infected individuals

41

2006

JAIDS

43

5

MARKOWITZ M

efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with hiv-1 infection in power 1 and 2: a pooled subgroup analysis of data from two randomised trials

37

2007

LANCET

369

9568

CLOTET B

emergence of cxcr4-using human immunodeficiency virus type 1 (hiv-1) variants in a minority of hiv-1-infected patients following treatment with the ccr5 antagonist maraviroc is from a pretreatment cxcr4-using virus reservoir

36

2006

J VIROL

80

10

WESTBY M

safety and efficacy of the hiv-1 integrase inhibitor raltegravir (mk-0518) in treatment-experienced patients with multidrug-resistant virus: a phase ii randomised controlled trial

33

2007

LANCET

369

9569

GRINSZTEJN B

efficacy and safety of tmc114/ritonavir in treatment-experienced hiv patients: 24-week results of power 1

33

2007

AIDS

21

4

KATLAMA C

human immunodeficiency virus type 1 coreceptor switching: v1/v2 gain-of-fitness mutations compensate for v3 loss-of-fitness mutations

32

2006

J VIROL

80

2

PASTORE C

novel hiv-1 integrase inhibitors derived from quinolone antibiotics

27

2006

J MED CHEM

49

5

SATO M

hiv type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a ccr5 inhibitor: aids clinical trial group a5211

22

2007

CLIN INFECT DIS

44

4

WILKIN TJ

phase 2 study of the safety and efficacy of vicriviroc, a ccr5 inhibitor, in hiv-1-infected, treatment experienced patients: aids clinical trials group 5211

19

2007

J INFEC DIS

196

2

GULICK RM

development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism

15

2007

ANTIMICROB AGENTS CHEMOTHER

51

2

WHITCOMB JM

the hunt for hiv-1 integrase inhibitors

15

2006

AIDS PATIENT CARE STDS

20

7

LATAILLADE M

efficacy and safety of tmc125 (etravirine) in treatment-experienced hiv-1-infected patients in duet-2: 24-week results from a randomised, double-blind, placebo-controlled trial

13

2007

LANCET

370

9581

LAZZARIN A

RF ID

核心论文数

去重被引次数

总被引次数

平均出版年

是否为热点

6501

12

673

1964

2003.3

Yes

RF的关键词

human immunodeficiency virus (hiv)-infected adults receiving antiretroviral therapy; human immunodeficiency virus infection; cardiovascular disease risk factors; randomized double-blind placebo-controlled study; cardiovascular risk

论文题目

被引

年份

刊名

卷

期

第一作者

combination antiretroviral therapy and the risk of myocardial infarction

386

2003

N ENGL J MED

349

21

FRIIS-MOLLER N

cardiovascular disease risk factors in hiv patients - association with antiretroviral therapy. results from the dad study

186

2003

AIDS

17

8

FRIIS-MOLLER N

cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection

183

2003

N ENGL J MED

348

8

BOZZETTE SA

medical progress - cardiovascular risk and body-fat abnormalities in hiv-infected adults.

173

2005

N ENGL J MED

352

1

GRINSPOON S

an objective case definition of lipodystrophy in hiv-infected adults: a case-control study

165

2003

LANCET

361

9359

CARR A

abacavir substitution for nucleoside analogs in patients with hiv lipoatrophy - a randomized trial

153

2002

JAMA-J AM MED ASSN

288

2

CARR A

protease inhibitors and cardiovascular outcomes in patients with hiv-1

152

2002

LANCET

360

9347

HOLMBERG SD

increased risk of myocardial infarction with duration of protease inhibitor therapy in hiv-infected men

144

2003

AIDS

17

17

MARY-KRAUSE M

guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (hiv)-infected adults receiving antiretroviral therapy: recommendations of the hiv medicine association of the infectious disease society of america and the

138

2003

CLIN INFECT DIS

37

5

DUBE MP

substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection

129

2003

N ENGL J MED

349

11

MARTINEZ E

no effect of rosiglitazone for treatment of hiv-1 lipoatrophy: randomised, double-blind, placebo-controlled trial

90

2004

LANCET

363

9407

CARR A

rosiglitazone in the treatment of haart-associated lipodystrophy - a randomized double-blind placebo-controlled study

65

2003

ANTIVIR THER

8

3

SUTINEN J

RF ID

核心论文数

去重被引次数

总被引次数

平均出版年

是否为热点

8131

8

629

1438

2004.5

No

RF的关键词

adult hiv infection; hiv-1 infection; initial treatment; initial therapy; tenofovir df

论文题目

被引

年份

刊名

卷

期

第一作者

efficacy and safety of tenofovir df vs stavuldine in combination therapy in antiretroviral-naive patients - a 3-year randomized trial

317

2004

JAMA-J AM MED ASSN

292

2

GALLANT JE

lopinavir-ritonavir versus nelfinavir for the initial treatment of hiv infection

274

2002

N ENGL J MED

346

26

WALMSLEY S

treatment for adult hiv infection - 2006 recommendations of the international aids society-usa panel

207

2006

JAMA-J AM MED ASSN

296

7

HAMMER SM

comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2nn study

176

2004

LANCET

363

9417

VAN LETH F

triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of hiv-1 infection

166

2004

N ENGL J MED

350

18

GULICK RM

comparison of sequential three-drug regimens as initial therapy for hiv-1 infection

143

2003

N ENGL J MED

349

24

ROBBINS GK

tenofovir df, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for hiv

134

2006

N ENGL J MED

354

3

GALLANT JE

tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in anti retroviral-naive patients - virologic, immunologic, and morphologic changes - a 96-week analysis

21

2006

JAIDS

43

5

POZNIAK AL

RF ID

核心论文数

去重被引次数

总被引次数

平均出版年

是否为热点

9997

5

565

1051

2003.4

Yes

RF的关键词

recently hiv infected patient antiretroviral drug resistance; primary hiv-1 drug resistance; recently infected persons; drug-resistant hiv-1 variants

论文题目

被引

年份

刊名

卷

期

第一作者

antiretroviral-drug resistance among patients recently infected with hiv

437

2002

N ENGL J MED

347

6

LITTLE SJ

antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an international aids society-usa panel

276

2003

CLIN INFECT DIS

37

1

HIRSCH MS

time trends in primary hiv-1 drug resistance among recently infected persons

186

2002

JAMA-J AM MED ASSN

288

2

GRANT RM

prevalence of drug-resistant hiv-1 variants in untreated individuals in europe: implications for clinical management

88

2005

J INFEC DIS

192

6

WENSING AMJ

infection with multidrug resistant, dual-tropic hiv-1 and rapid progression to aids: a case report

64

2005

LANCET

365

9464

MARKOWITZ M

RF ID

核心论文数

去重被引次数

总被引次数

平均出版年

是否为热点

10691

5

536

975

2003.2

No

RF的关键词

hiv-1-infected patients starting highly active antiretroviral therapy; start highly active antiretroviral therapy; initiating antiretroviral therapy; potent antiretroviral therapy; different cd4(+) cell strata

论文题目

被引

年份

刊名

卷

期

第一作者

prognosis of hiv-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies

384

2002

LANCET

360

9327

EGGER M

decline in the aids and death rates in the eurosida study: an observational study

288

2003

LANCET

362

9377

MOCROFT A

survival benefit of initiating antiretroviral therapy in hiv-infected persons in different cd4(+) cell strata

118

2003

ANN INTERN MED

138

8

PALELLA FJ

effect of medication adherence on survival of hiv-infected adults who start highly active antiretroviral therapy when the cd4(+) cell count is 0.200 to 0.350 x 10(9) cells/l

106

2003

ANN INTERN MED

139

10

WOOD E

long-term effectiveness of potent antiretroviral therapy in preventing aids and death: a prospective cohort study

79

2005

LANCET

366

9483

STERNE JAC

RF ID

核心论文数

去重被引次数

总被引次数

平均出版年

是否为热点

12225

5

529

1107

2002.8

No

RF的关键词

hiv-1 fusion inhibitor efficacy; patients receiving fusion inhibitor (t-20) monotherapy; entry inhibitors correlates; drug-resistant hiv-1; fusion kinetics

论文题目

被引

年份

刊名

卷

期

第一作者

enfuvirtide, an hiv-1 fusion inhibitor, for drug-resistant hiv infection in north and south america

294

2003

N ENGL J MED

348

22

LALEZARI JP

emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (t-20) monotherapy

273

2002

ANTIMICROB AGENTS CHEMOTHER

46

6

WEI XP

efficacy of enfuvirtide in patients infected with drug-resistant hiv-1 in europe and australia

266

2003

N ENGL J MED

348

22

LAZZARIN A

sensitivity of hiv-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics

165

2002

PROC NAT ACAD SCI USA

99

25

REEVES JD

the entry of entry inhibitors: a fusion of science and medicine

109

2003

PROC NAT ACAD SCI USA

100

19

MOORE JP

RF ID

核心论文数

去重被引次数

总被引次数

平均出版年

是否为热点

7635

4

95

215

2006.0

No

RF的关键词

highly active antiretroviral therapy; primary care sites; rural district; high-income countries; effectiveness assessment

论文题目

被引

年份

刊名

卷

期

第一作者

mortality of hiv-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries

94

2006

LANCET

367

9513

BRAITSTEIN P

scaling up of highly active antiretroviral therapy in a rural district of malawi: an effectiveness assessment

45

2006

LANCET

367

9519

FERRADINI L

rapid scale-up of antiretroviral therapy at primary care sites in zambia - feasibility and early outcomes

42

2006

JAMA-J AM MED ASSN

296

7

STRINGER JSA

adherence to antiretroviral therapy in sub-saharan africa and north america - a meta-analysis

34

2006

JAMA-J AM MED ASSN

296

6

MILLS EJ

RF ID

核心论文数

去重被引次数

总被引次数

平均出版年

是否为热点

14236

3

54

165

2006.3

No

RF的关键词

antiretroviral treatment cd4+count-guided interruption; cd4-guided scheduled treatment interruptions compared; antiretroviral drugs; staccato randomised trial

论文题目

被引

年份

刊名

卷

期

第一作者

cd4+count-guided interruption of antiretroviral treatment

86

2006

N ENGL J MED

355

22

EL-SADR WM

class of antiretroviral drugs and the risk of myocardial infarction

44

2007

N ENGL J MED

356

17

FRIIS-MOLLER N

cd4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with hiv-1: results of the staccato randomised trial

35

2006

LANCET

368

9534

ANANWORANICH J